United Therapeutics Corporation (NASDAQ:UTHR) Shares Acquired by Meeder Asset Management Inc.

Meeder Asset Management Inc. lifted its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 11,855.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,152 shares of the biotechnology company's stock after purchasing an additional 2,134 shares during the period. Meeder Asset Management Inc.'s holdings in United Therapeutics were worth $663,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Anchor Investment Management LLC grew its position in United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. Hohimer Wealth Management LLC boosted its stake in shares of United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after acquiring an additional 37 shares in the last quarter. Applied Finance Capital Management LLC boosted its stake in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after acquiring an additional 40 shares in the last quarter. Dunhill Financial LLC boosted its stake in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of United Therapeutics by 3.0% during the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company's stock worth $626,000 after acquiring an additional 52 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,681 shares of company stock valued at $21,318,359. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 7.1%

UTHR stock traded up $19.58 during midday trading on Friday, hitting $294.28. 2,428,905 shares of the company's stock were exchanged, compared to its average volume of 509,448. The business has a 50-day simple moving average of $298.39 and a two-hundred day simple moving average of $314.07. The stock has a market capitalization of $13.27 billion, a PE ratio of 11.49, a P/E/G ratio of 6.15 and a beta of 0.53. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the business earned $5.85 earnings per share. The company's quarterly revenue was up 11.7% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday. Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Wells Fargo & Company decreased their target price on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Finally, UBS Group decreased their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $379.69.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.